Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $7.0 million.

  • Iradimed's Cash from Operations fell 2336.23% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year increase of 620.65%. This contributed to the annual value of $25.6 million for FY2024, which is 9030.4% up from last year.
  • Iradimed's Cash from Operations amounted to $7.0 million in Q3 2025, which was down 2336.23% from $7.7 million recorded in Q2 2025.
  • Iradimed's 5-year Cash from Operations high stood at $9.1 million for Q3 2024, and its period low was $943081.0 during Q1 2021.
  • In the last 5 years, Iradimed's Cash from Operations had a median value of $3.9 million in 2024 and averaged $4.2 million.
  • Per our database at Business Quant, Iradimed's Cash from Operations crashed by 6463.89% in 2023 and then soared by 55454.29% in 2024.
  • Quarter analysis of 5 years shows Iradimed's Cash from Operations stood at $3.4 million in 2021, then dropped by 9.72% to $3.0 million in 2022, then rose by 28.75% to $3.9 million in 2023, then soared by 53.02% to $6.0 million in 2024, then increased by 16.69% to $7.0 million in 2025.
  • Its Cash from Operations was $7.0 million in Q3 2025, compared to $7.7 million in Q2 2025 and $4.3 million in Q1 2025.